These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3091231)

  • 1. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children.
    Farrell K; Abbott FS; Orr JM; Applegarth DA; Jan JE; Wong PK
    Can J Neurol Sci; 1986 Aug; 13(3):252-5. PubMed ID: 3091231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.
    Gal P; Oles KS; Gilman JT; Weaver R
    Neurology; 1988 Mar; 38(3):467-71. PubMed ID: 3126410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of valproic acid in plasma or serum by solid-phase column extraction and gas-liquid chromatography.
    Lin W; Kelly AR
    Ther Drug Monit; 1985; 7(3):336-43. PubMed ID: 3931313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships.
    Braathen G; Theorell K; Persson A; Rane A
    Epilepsia; 1988; 29(5):548-52. PubMed ID: 3137019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum biotinidase activity in children treated with valproic acid and carbamazepine.
    Castro-Gago M; Gómez-Lado C; Eirís-Puñal J; Díaz-Mayo I; Castiñeiras-Ramos DE
    J Child Neurol; 2010 Jan; 25(1):32-5. PubMed ID: 19458381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid free fraction in epileptic children under chronic monotherapy.
    Riva R; Albani F; Franzoni E; Perucca E; Santucci M; Baruzzi A
    Ther Drug Monit; 1983 Jun; 5(2):197-200. PubMed ID: 6410546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children.
    Cepelak I; Zanić Grubisić T; Mandusić A; Rekić B; Lenicek J
    Clin Chim Acta; 1998 Aug; 276(2):121-7. PubMed ID: 9764730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic valproic acid and coantiepileptic drug therapy and incidence of increases in serum liver enzymes.
    Haidukewych D; John G
    Ther Drug Monit; 1986; 8(4):407-10. PubMed ID: 3103262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.